tbuckley/cabot-search huggingface dataset:
Insulin-like growth factor-1 receptor expression in invasive ductal breast carcinoma is related to tumor characteristics and prognosis
Authors: H. Hartog, B. Van der Vegt, W. T. Van der Graaf, H. M. Boezen, G. H. De Bock, J. Wesseling
Journal: Journal of Clinical Oncology (2007)

10563 Background: The role of the insulin-like growth factor-1 receptor (IGF-1R) in the outcome of breast cancer is poorly understood. Therefore, we analyzed the prognostic value of IGF-1R expression in relation to clinically relevant tumor characteristics. Methods: Expression of IGF-1R, insulin receptor, estrogen receptor (ER), progesterone receptor (PR), HER2 receptor, epidermal growth factor receptor and phosphorylated Akt (pAkt) was determined on tissue microarrays comprising primary invasive ductal breast carcinoma samples of a consecutive series of 221 patients. Patients presented at the University Medical Center Groningen between 1996 and 2001. Patient records were reviewed for clinical and tumor parameters. Cytoplasmic and membranous IGF-1R staining were scored separately, as the relevance of IGF-1R cellular localization is yet unknown. Associations were tested by Chi-square, Log Rank test and Cox regression analysis. Results: Overall, IGF-1R expression was present in 79% of the tumors. Cytoplasmic staining was present in 69%, membranous in 52%, staining was combined cytoplasmic and membranous in 42% of the tumors. Cytoplasmic, but not membranous, IGF-1R staining was associated with expression of ER (p&lt;0.001), PR (p=0.001), pAkt (p=0.04), and increased relapse free and overall survival (RFS, p=0.01; OS, p=0.006). No correlations with other parameters were found. In ER/PR positive, HER2 negative tumors, but not in HER2 positive tumors, cytoplasmic IGF-1R expression correlated with increased RFS (p=0.002) and OS (p=0.001). In contrast, in triple negative tumors cytoplasmic and membranous expression of IGF-1R were both significantly associated with shorter RFS (p=0.02, p=0.04, resp.). In multivariate analysis, cytoplasmic IGF-1R expression was an independent prognostic factor for OS (HR 0.3, 95% CI 0.1–0.9, p=0.035). Conclusions: Cytoplasmic IGF-1R expression in invasive ductal breast carcinoma is associated with hormone receptor expression, phosphorylated Akt and good prognosis. Surprisingly, triple negative tumors expressing IGF-1R have a worse prognosis than those without. These results suggest that IGF-1R targeted therapy may have additional value in the treatment of triple negative tumors. No significant financial relationships to disclose.
Myocardial Infarction in a Patient With Hypertrophic Cardiomyopathy but Normal Coronary Arteries
Authors: Shuheng Li, Xiaoxin Sun, Zongyao Zhang, Zuo-Xiang He
Journal: Clinical Nuclear Medicine (2017)

A 57-year-old man with a history of hypertrophic cardiomyopathy diagnosed by echocardiography experienced atypical chest pain and dyspnea for 6 months. A rest Tc-MIBI myocardial SPECT imaging and a F-FDG myocardial PET/CT imaging were performed, which showed multiple matched myocardial perfusion/metabolism defects in the left ventricle, indicating scar tissue. Surprisingly, subsequent contrast coronary angiography revealed no significant coronary artery stenosis.
Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model
Authors: Ran He, Xinxin Yang, Cheng Liu, Xiangyu Chen, Lin Wang, Minglu Xiao, Jianqiang Ye, Yuzhang Wu, Lilin Ye
Journal: Cellular and Molecular Immunology (2017)
EFFECTS OF TICAGRELOR VERSUS CLOPIDOGREL IN FIBRINOLYTIC-TREATED STEMI PATIENTS UNDERGOING EARLY PCI
Authors: Payam Dehghani, Andrea Lavoie, Shahar Lavi, Rodney Zimmermann, Jeff Booker, Warren Cantor, Shamir Mehta, Sebastian Harenberg, Jennifer Crawford, Sheila Kelly, Asim Cheema
Journal: Journal of the American College of Cardiology (2017)
SIZING AORTIC VALVE ANNULUS FOR TRANSCATHETER AORTIC VALVE PROSTHESIS SELECTION: IMPACT OF AORTIC VALVE CALCIFICATION BURDEN ON THE AGREEMENT BETWEEN AUTOMATED 3-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY AND MULTIDETECTOR ROW COMPUTED TOMOGRAPHY
Authors: Tomaz Podlesnikar, Edgard Prihadi, Philippe Rosendael, Elise Vollema, Frank Kley, Nina Ajmone Marsan, Zlatko Fras, Jeroen Bax, Victoria Delgado
Journal: Journal of the American College of Cardiology (2017)
ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment.
Authors: Susan Elaine Bates, Maria Liza Lindenberg, Christine Bryla, Mauricio Emmanuel Burotto Pichun, Nicholas Patronas, Laleh Amiri-Kordestani, Esther Mena Gonzalez, Tito Fojo, Sanjeeve Balasubramaniam, Peter L. Choyke
Journal: Journal of Clinical Oncology (2015)

2552 Background: ANG1005 is a novel drug conjugate consisting of 3 molecules of paclitaxel covalently linked to Angiopep-2, designed to cross the blood brain barrier (BBB) via endocytosis after binding to LRP-1. A multi-center Phase II study with the primary endpoint of intra-cranial response in patients with brain metastases from breast cancer is ongoing. At the NCI a biomarker substudy is evaluating 18F-FLT (3'-Fluoro-3' deoxythymidine)-PET for response assessment. Methods: ANG1005 was administered IV at 550 mg/m2 q21d to patients with measurable brain metastases from breast cancer. All patients underwent imaging before and after cycle 1 with 18F-FLT, a thymidine analog and novel imaging agent; its retention reflecting DNA synthesis. We compared FLT PET images with Gd-MRI contrast scans for brain metastasis detection and response assessment. Both dynamic and static images were obtained. The % change after ANG1005 was determined, with 20% considered significant. Nine of 10 planned patients have been accrued. Results: Eighteen metastatic brain lesions in 8 patients were analyzed. The maximum standard uptake value (SUVmax) ranged from 0.8 to 4.0 in the baseline scan, mean 1.8. Twelve of the 18 lesions showed a > 20% change post therapy. The average % change was -24.8% (range: 11 to -66.8%) using SUVmax, and -7.7% using tumor to normal ratios. The FLT-PET uptake reduction exceeded the MRI result in 4 patients. Two patients had confirmed partial responses lasting 6 and 14 cycles, respectively. Six patients had stable disease, receiving a median 6 cycles. The best tumor reductions, as determined by MRI per CNS RECIST v1.1 ranged from -5% to -60% in lesion size, compared to baseline. Conclusions: CNS metastases from breast cancer require new CNS-directed therapies designed to cross the BBB, such as the paclitaxel conjugate ANG1005. Given that contrast-enhanced MRI detection of brain metastases represents gadolinium leakage through the BBB, rather than actual tumor volume, better approaches are needed to assess drug efficacy. Pilot evaluations of FLT-PET imaging of brain metastases suggest that it is a promising tool that may serve as a complementary assessment method for CNS disease. Clinical trial information: NCT01480583.
ARTERIAL ELASTANCE DRIVES VENTILATORY INEFFICIENCY IN SYSTOLIC HEART FAILURE
Authors: Leo F. Buckley, Salvatore Carbone, Justin Canada, Cory Trankle, Sanah Christopher, Jessica Regan, Michele Mattia Viscusi, Dave L. Dixon, Nayef Abouzaki, Dinesh Kadariya, Ross Arena, Antonio Abbate, Benjamin Van Tassell
Journal: Journal of the American College of Cardiology (2017)
Racial differences in upper extremity function for breast cancer survivors.
Authors: Lorraine Tiera Dean, Angela DeMichele, Susan Q Li, Christopher Colameco, Alisa Jane Stephens-Shields, Morgan Coursey, Jun J. Mao
Journal: Journal of Clinical Oncology (2015)

9569 Background: Over 35% of breast cancer survivors face upper extremity disability due to breast cancer surgery, radiation, or chemotherapy to the upper body region. Race may be a key patient characteristic in disability, given that race is associated with factors related to poor functioning, including weight gain after breast cancer, disease stage, and treatment type. Studies of breast cancer survivors have not explicitly evaluated the associations between race and upper extremity disability using validated tools. Methods: The Quick-DASH (Disabilities of the Arm, Shoulder and Hand) is an 11-item self-administered questionnaire that has been validated for breast cancer survivors to assess global arm function over the past 7 days. The cross-sectional analysis assessed whether or not Black or White women had greater upper extremity disability, evidenced by higher Quick-DASH scores, in a population of 697 breast cancer survivors in the Wellness After Breast Cancer-II study. Linear regression estimated the relationship between race and Quick-DASH score, adjusting for demographics, body mass index (BMI), treatment type (lumpectomy, mastectomy, radiation, chemotherapy, and reconstruction), and other physical factors. Results: Black women had significantly higher BMI and age, were less likely to have had mastectomy, and had 7.7 points higher average Quick-DASH score than White (p < 0.001) women. After adjustment for demographics, BMI, treatment type, and other physical factors, Black women had an average 4.1-point (95% CI: 0.96-7.92) higher Quick-DASH score (p = 0.01) compared with White women. Mediation analysis suggested that BMI reduced the association between race and disability by 29.7%. Conclusions: Black women’s Quick-DASH scores indicated clinically significant worse functioning, which were partially mediated by higher BMIs. Black patients may present in clinic with both worse functioning and higher BMI. Findings suggest that more research is needed to elucidate the relationship between race, BMI, and upper extremity disability, including determining additional factors beyond BMI that account for the relationship between race and disability.
Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)
Authors: Emma C Morris, Thomas Andrew Fox, Siobhan Burns, Ben Carpenter, Kirsty J Thomson, David Lowe, Adele K. Fielding, Karl S Peggs, Panagiotis Kottaridis, Victoria Grandage, Shari Denovan, Sarah Grace, Julia Dahlstrom, Sarita Workman, Andrew Symes, Stephen Mackinnon, Ronjon Chakraverty, Rachael Hough
Journal: Blood (2016)
IMPACT OF TREATMENT CROSSOVERS ON CLINICAL OUTCOMES IN THE RATE AND RHYTHM CONTROL STRATEGIES FOR ATRIAL FIBRILLATION: INSIGHTSFROM THE AFFIRM (ATRIAL FIBRILLATION FOLLOW-UP INVESTIGATION OF RHYTHM MANAGEMENT) TRIAL
Authors: Fnu Abhishek, Zheng Zhang, Ziling Qin, Samuel C. Dudley, Yanbing Wang, Kaustubh Dabhadkar, Marwan Refaat, Moussa Mansour, Jeremy Ruskin, Edwin Heist
Journal: Journal of the American College of Cardiology (2017)
Kinetics of Endogenous CaMKII Required for Synaptic Plasticity Revealed by Optogenetic Kinase Inhibitor
Authors: Hideji Murakoshi, Myung Eun Shin, Paula Parra-Bueno, Erzsebet M. Szatmari, Akihiro C.E. Shibata, Ryohei Yasuda
Journal: Neuron (2017)

Elucidating temporal windows of signaling activity required for synaptic and behavioral plasticity is crucial for understanding molecular mechanisms underlying these phenomena. Here, we developed photoactivatable autocamtide inhibitory peptide 2 (paAIP2), a genetically encoded, light-inducible inhibitor of CaMKII activity. The photoactivation of paAIP2 in neurons for 1–2 min during the induction of LTP and structural LTP (sLTP) of dendritic spines inhibited these forms of plasticity in hippocampal slices of rodents. However, photoactivation ∼1 min after the induction did not affect them, suggesting that the initial 1 min of CaMKII activation is sufficient for inducing LTP and sLTP. Furthermore, the photoactivation of paAIP2 expressed in amygdalar neurons of mice during an inhibitory avoidance task revealed that CaMKII activity during, but not after, training is required for the memory formation. Thus, we demonstrated that paAIP2 is useful to elucidate the temporal window of CaMKII activation required for synaptic plasticity and learning.
Contrast-enhanced spectral mammography (CESM) compared with breast MRI for breast cancer detection.
Authors: Lydia Liao, Luna Li, Pauline Germaine, Elizabeth Tinney
Journal: Journal of Clinical Oncology (2015)

11069 Background: Contrast-enhanced spectral mammography (CESM) is a new study to detect contrast enhancing malignancy that may not be visible on conventional mammogram. Limited studies have shown that adding CESM to diagnostic workup in adjunct with mammogram and breast ultrasound does increase sensitivity for breast cancer detection. More studies are needed to compare the sensitivity of CESM to BMRI to further define the role of CESM in breast cancer diagnosis. Methods: This study involved 60 malignant breasts in 58 women retrospectively chosen from of 1020 patients in our institution during the period of October 2012 to October 2014. Both CESM and BMRI were done for each patient within 30 days. The positive findings were confirmed by pathology reports. The number of malignant lesions was quantified. The size of lesions was classified into three categories based on standard of breast cancer stages. The enhancement intensity on both studies has been quantified based on a scale of 0-3. The scores of each case were calculated for average size of index lesion and statistical analysis. Sensitivity and positive predictive value (PPV) were calculated for each study. Morphology consistence was evaluated by the percentage of the consistent findings between CESM and BMRI. The mean study time for each test was recorded and analyzed for statistical significance. Results: Both CESM and BMRI are shown to have sensitivity of 98% for breast cancer detection. No statistical significance was identified on the mean size of index cancer (p = 0.39). The enhancement intensity of breast parenchyma is significantly lower on CESM than on BMRI (p < 0.01). The mean score of enhancement intensity of index lesions on CESM was significantly less than that for BMRI (p < 0.01). The smallest cancer can be detected by both CESM and BMRI is less than 0.5 cm. Morphology consistence was 59/60 (98.3%). CESM has a higher PPV than BMRI (98.0% versus 92.6%). The average test time for CESM is significantly shorter than BMRI (10 minutes versus 25 minutes). Conclusions: CESM and BMRI are consistent on morphology and equal sensitivity for detection of breast cancer lesions. CESM has less enhancement intensity than BMRI and higher PPV (reflecting a higher specificity) than BMRI.
ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY
Authors: Lauren Beth Cooper, Lina Benson, Robert Mentz, Gianluigi Savarese, Adam DeVore, Juan Jesus Carrero, Ulf Dahlstrom, Stefan Anker, Mitja Lainscak, Adrian Hernandez, Bertram Pitt, Lars Lund
Journal: Journal of the American College of Cardiology (2017)
COMPREHENSIVE NEXT GENERATION SEQUENCING ASSAY FOR IDENTIFYING PATHOGENIC VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASES
Authors: Eugene Joseph, Arun Manoharan, Krishan Kania, Nina Masters, Roman Shraga, Bonny Patel, Andrew Pollock, Robert Wisotzkey, Malgorzata Jaremko, Sasha Parets, Rebecca Fox, Neha Kumar, Alexander Bisignano, Oscar Puig
Journal: Journal of the American College of Cardiology (2017)
Adoptive Therapy with Human CD19 (hCD19)-Targeted T Cells Further Modified to Express IL-12 Overcome the Need for Prior Lymphodepletion to Eradicate Established hCD19+ Tumors and Induce B Cell Aplasias In Immune Competent hCD19+ Transgenic Mice
Authors: Erik Hayman, James Lee, Hollie J. Pegram, Renier Brentjens
Journal: Blood (2010)
Allogeneic Cytokine-Induced Killer Cells Traffick to GVHD Target Tissue but Cause Less GVHD, While Retaining Tumor Cytotoxicity and Facilitating Bone Marrow Engraftment.
Authors: Ryosei Nishimura, Jeanette Baker, Andreas Beilhack, Robert Negrin
Journal: Blood (2006)
Expression of CD133 and poor outcome in neuroblastoma associated with chemoresistance mediated by AKT pathway
Authors: H. Sartelet, E. Haddad, T. Imbriglio, M. Arsenault, S. Ohta, S. Barrette, D. Sinnett, C. Laverdiere, L. Oligny, G. Vassal
Journal: Journal of Clinical Oncology (2009)

10007 Background: Neuroblastoma is a frequent childhood cancer with very heterogeneous prognosis. Recent studies showed that CD133 expression is an independent prognostic marker for low survival in several cancers like medulloblastoma. The aim of our study is to determine the prognostic value of CD133 expression in a large population of neuroblastoma and to determine the chemoresistance of neuroblasts expressing CD133. Methods: 280 tumor samples of neuroblastoma were screened for CD133 expression. Patients had a median follow-up of 7.15 years. One hundred eighteen patients were under one year of age with a median age of 27 months. There were 67 stage 1, 46 stage 2, 43 stage 3, 99 stage 4, and 25 stage 4S. The association of CD133 expression with relapse and survival were determined through univariate and multivariate analysis. Sensitivity of purified CD133+ neuroblasts isolated from 2 human neuroblastoma cell lines (SKNSH and NB10) to doxorubicin, vincristine and cisplatin was evaluated in vitro, as single agents or in combination with LY294002, a AKT inhibitor. Results: CD133 was expressed in 95 of 280 tumors (33%). There was a significant association between CD133 expression and the following poor prognosis co-variates: age (p&lt;0.0001), INSS stage (p&lt;0.0001), MYCN amplification (p&lt;0.0001). Patients with a CD133+ tumor had a three year event-free and overall survival of 43±5% and 51±5%, respectively, as compared to patients with a CD133- tumor with 88±2% (P&lt;0.001) and 95±2% (p&lt;0.001). In a multivariate model, CD133 expression was independently associated with a decreased overall survival (p = 0.003) in the entire cohort. In vitro purified CD133+ neuroblasts were significantly resistant to chemotherapy as compared to their CD133- cells counterpart, but not in presence of the AKT inhibitor. In vitro treatment of unsorted neuroblasts with the three anticancer drugs significantly enriched the CD133+ subpopulation but not in presence of the AKT inhibitor. CD133plus; significantly expressed higher levels of activated proteins in the AKT pathway than CD133−. Conclusions: CD133 is independently associated with a worse outcome in patents with neuroblastoma. This prognosis factor is associated with in vitro resistance to chemotherapy involving activation of the AKT pathway. No significant financial relationships to disclose.
Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Alessandra Di Bacco, Nizar J. Bahlis, Nikhil C Munshi, Hervé Avet-Loiseau, Tamás Masszi, Luísa Viterbo, Ludek Pour, Peter Ganly, Michele Cavo, Christian Langer, Shaji Kumar, S. Vincent Rajkumar, Deborah Berg, Jianchang Lin, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, Dixie-Lee Esseltine, Katarina Luptakova, Helgi van de Velde, Paul G. Richardson, Philippe Moreau
Journal: Blood (2016)
CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)
Authors: MIchela Sica, Tommaso Rondelli, Patrizia Ricci, Maria De Angioletti, Antonio M Risitano, Rosario Notaro
Journal: Blood (2016)
Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer
Authors: J. I. Mayordomo, J. M. Baena, L. Cirera, P. Sanchez-Rovira, M. J. Godes, A. Galan, E. Jimenez-Orozco, M. Muñoz, I. Tusquets, M. J. Sanchez
Journal: Journal of Clinical Oncology (2009)

1001 Background: Chemotherapy for patients with metastatic breast cancer is not curative. Anthracyclines and taxanes are among the most active drugs. Optimal duration of chemotherapy in women with metastatic breast cancer is an open issue. Should they receive chemotherapy to progression or should chemotherapy be stopped after a fixed number of courses? The excellent safety profile of weekly paclitaxel prompted us to evaluate its role as maintenance treatment in this setting. The primary objective was to determine if addition of maintenance weekly paclitaxel prolongs progression-free survival in women with metastatic breast cancer on first-line chemotherapy. Secondary objectives included overall survival and toxicity. Methods: Following Ethical Committee approval and informed consent, from 2002 to 2006 180 women with metastatic breast cancer and no prior chemotherapy for metastatic disease were randomized 1:1 in the TASMAN phase III trial to: 3 courses of epirubicin 100 mg/m2 day 1 q 21 days, followed by 3 courses of paclitaxel 225 mg/m2 day 1 q 21 days, without further chemotherapy or hormonal therapy until progression (arm A), or 3 courses of epirubicin followed by 3 courses of paclitaxel and then maintenance with paclitaxel 60 mg/m2 day 1 q 7 days until progression or unacceptable toxicity (arm B). Results: Median age: 51 years (range: 30–73). Median performance status (ECOG): 0 (0–2). Sites of metastases: bone (36%), liver (20%), pleura and/or lung (19%), skin and/or lymph nodes (18%). No grade 3–4 toxicities were seen with maintenance chemotherapy. As of January 1, 2009, 18 patients remained progression-free and 48 were alive, with a minimum follow-up of 2 years. Median progression-free survival was 8 months for arm A versus 12 months for arm B (p = 0.1, logrank). Median overall survival was 24 months for each arm (p = 0.7). Conclusions: Maintenance chemotherapy with weekly paclitaxel following first-line chemotherapy with anthracycline and taxane is well tolerated but does not significantly increase progression-free survival. No significant financial relationships to disclose.
NON-INVASIVE CORONARY FLOW RESERVE PREDICTS MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH PRIOR CORONARY ARTERY BYPASS GRAFTING
Authors: Amjad M. Ahmed, Ihab Sulaiman, Mousa Alfaris, Dalia Ahmed, Ahmed Aljizeeri, Ahmed Alsaileek, Abdulbaset Sulaiman, Sherif Sakr, Mouaz Al-Mallah
Journal: Journal of the American College of Cardiology (2017)
COMPLIANCE TO UPDATED AHA/ACC QUALITY MEASURES AMONG PATIENTS WITH ATRIAL FIBRILLATION IN JAPAN AND ITS ASSOCIATION WITH THEIR QUALITY OF LIFE
Authors: Taku Inohara, Shun Kohsaka, Takehiro Kimura, Ikuko Ueda, Nobuhiro Ikemura, Mitsuaki Sawano, Kazuaki Nakajima, Shin Kashimura, Akira Kunitomi, Yoshinori Katsumata, Takahiko Nishiyama, Nobuhiro Nishiyama, Yoshiyasu Aizawa, Keiichi Fukuda, Seiji Takatsuki
Journal: Journal of the American College of Cardiology (2017)
Allogeneic and Matched Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies Using a Modified Reduced Intensity Conditioning Regimen.
Authors: Marion Raflores, James Rossetti, John Lister, Richard Shadduck, John Lech, Robert Kaplan, Margaret Kennedy, Gisa Schunn
Journal: Blood (2005)
TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTICVALVE REPLACEMENT IN AORTIC STENOSIS PATIENTS AT LOW TO MODERATE RISK OF SURGERY: A META-ANALYSIS OF 25,737 PATIENTS’ DATA
Authors: Ahmed Elmaraezy, Abdelrahman Ibrahim Abushouk, Ammar Ismail, Farah Althaher, Ahmed Hesham Aboelmakarem, Ahmed Ramadan Abdallah, Moutaz Eltoomy, Hossam Mahmoud Hassan, Mohamed Mansour Saad, Aya Gamal Elmareazy, Ahmed Magdy Aboelfotoh, Mohammed Ahmed Shaheen, Osama Mahmoud Abdelaty, Soha Saad Ali, Moath Althaher
Journal: Journal of the American College of Cardiology (2017)